<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943486</url>
  </required_header>
  <id_info>
    <org_study_id>124174455522</org_study_id>
    <nct_id>NCT02943486</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2</brief_title>
  <acronym>MSCDTDFU</acronym>
  <official_title>Mesenchymal Stromal Cell Derivatives: a New Alternative and Potential Product for the Treatment of Diabetic Foot Ulcers 1 and 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autónoma de Bucaramanga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Autónoma de Bucaramanga</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the safety and efficacy of using mesenchymal stromal
      cell derivatives (dac-MSCs) in the treatment of chronic diabetic foot ulcers (type 1 and 2)
      in adults. A third of the participants will receive dac-MSCs and Triticum vulgare
      (Fitostimoline) in combination, the other third MSCs and Fitostimoline in combination, and
      the last third only Fitosimoline. This study will be a randomized, blind, and parallel and
      controlled-group trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conventional treatments such as dry, wet or active dressings are effective only in 50% of
      patients with diabetic foot ulcer. The remaining 50% of patients have non-responding
      recoveries that leads to amputation of the compromised limbs. Currently, the administration
      of mesenchymal stem cells (MSCs) in animal models or in small groups of patients with
      diabetic foot ulcer has shown to be safe and effective. Particularly, the use of these cells
      induce regeneration, both in the dermis and the epidermis. Nevertheless, MSC transplantation
      has some limitations, for instance, time restrictions in the availability of cells due to
      their isolation and expansion as well as the complex and costly large-scale production. In
      the same manner, the cryopreservation might cause deleterious effects that affect the
      biological activity of the cells and a medical professional should conduct the cell
      administration. In addition, different studies report variability in the results due to the
      inconsistency in the methods that they used (extraction protocols, cultivation, expansion and
      administration). The investigators' recent studies in mice with skin lesions, particularly
      type 1 diabetes, have shown that the presence of the cells is not necessary to promote skin
      regeneration and the administration of dac-MSCs is sufficient to stimulate would healing.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound size change</measure>
    <time_frame>One year</time_frame>
    <description>Wound size will be assessed using a SilhouetteMobile camera (digital planimetry)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Granulation tissue percentage</measure>
    <time_frame>One year</time_frame>
    <description>Images will be used to assess the amount of granulation tissue present in the wound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pigmentation change</measure>
    <time_frame>One year</time_frame>
    <description>Digital images will be used to evaluate color changes in the wound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Exudate</measure>
    <time_frame>One year</time_frame>
    <description>Visual observation of the wound to determine the presence of exudate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>dac-MSCs and Fitostimoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSCs and Fitostimoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fitostimoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical application of fitostimoline every other day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dac-MSCs</intervention_name>
    <description>Cell-free therapy</description>
    <arm_group_label>dac-MSCs and Fitostimoline</arm_group_label>
    <other_name>Cell-free therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MSCs</intervention_name>
    <description>Cell-based therapy</description>
    <arm_group_label>MSCs and Fitostimoline</arm_group_label>
    <other_name>Cell-based therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fitostimoline</intervention_name>
    <description>Triticum vulgare</description>
    <arm_group_label>dac-MSCs and Fitostimoline</arm_group_label>
    <arm_group_label>MSCs and Fitostimoline</arm_group_label>
    <arm_group_label>Fitostimoline</arm_group_label>
    <other_name>Triticum vulgare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between the ages of 40 and 80 years, inclusive, with Type 1 or 2
             diabetes as defined by the American Diabetes Association

          -  Stable glycemic control

          -  Transcutaneous oxygen measurement &gt; 30 mmHg

          -  Ulcer present at least for 1 month

          -  Wound size between 0.5 and 5 cm2

          -  Subjects that require endovascular surgical intervention

          -  Subjects must have adequate nutrition (albumin level &gt; 2 g/dL and prealbumin level &gt;
             15 mg/dL)

        Exclusion Criteria:

          -  Previous or current diagnoses with one of the following: cancer, symptomatic coronary
             artery disease, brain disease, kidney failure, blood disorders

          -  Taking immunosuppressive and cytotoxic drugs

          -  Presence of active systemic infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia L Sossa-Melo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autónoma de Bucaramanga</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia L Sossa-Melo, MD</last_name>
    <phone>+57 7 643 6261</phone>
    <phone_ext>587</phone_ext>
    <email>claudiasossa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martha L Arango-Rodríguez, Ph.D.</last_name>
    <phone>+57 679 7979</phone>
    <phone_ext>6086</phone_ext>
    <email>martha.arango@fosunab.com</email>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autónoma de Bucaramanga</investigator_affiliation>
    <investigator_full_name>Claudia Lucia Sossa Melo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Fitostimoline</keyword>
  <keyword>MSC derivatives</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

